Medigen Vaccine Biologics Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-165.64	-80.47	-1,160	-1,475	1,410	-674.28
Depreciation & Amortization	138.87	134.99	130	127.26	112.33	122.21
Other Amortization	1.32	1.45	1.17	0.63	0.22	0.04
Loss (Gain) From Sale of Assets	8.43	-0.41	-	-	-	-19.73
Loss (Gain) From Sale of Investments	-	-1.42	9.64	16.55	0.07	0.06
Stock-Based Compensation	30.31	14.16	18.31	75.61	68.82	44.66
Other Operating Activities	20.61	71.32	-16.66	19.32	-0.02	-2.87
Change in Accounts Receivable	38.12	31.08	45.29	445.79	-635.73	-4.46
Change in Inventory	-44.06	-68.43	161.15	18.71	-486.06	-69.04
Change in Accounts Payable	6.97	-12.5	-82.64	21.72	65.63	19.28
Change in Unearned Revenue	-	-	-	-111.41	111.41	-
Change in Other Net Operating Assets	-10.92	-49.03	411.02	-353.41	-67.03	-5.84
Operating Cash Flow	24	40.75	-482.56	-1,214	579.89	-589.97
Capital Expenditures	-52.29	-34.3	-38.69	-139.17	-133.63	-99.25
Sale of Property, Plant & Equipment	1.67	0.87	-	-	120	29.69
Sale (Purchase) of Intangibles	-1.83	-0.68	-2.27	-1.17	-1.34	-6.05
Investment in Securities	-279.6	1,050	636.38	-2,279	-881.8	-
Other Investing Activities	0.82	1.29	74.4	134.74	-33.93	-0.69
Investing Cash Flow	-331.23	1,018	669.83	-2,285	-930.69	-76.3
Short-Term Debt Issued	-	-	-	-	30	30
Long-Term Debt Issued	-	-	-	1,755	-	-
Total Debt Issued	-	-	-	1,755	30	30
Short-Term Debt Repaid	-	-	-	-	-30	-60
Long-Term Debt Repaid	-	-1,740	-11.78	-11.56	-1.93	-441.76
Total Debt Repaid	-38.6	-1,740	-11.78	-11.56	-31.93	-501.76
Net Debt Issued (Repaid)	-38.6	-1,740	-11.78	1,744	-1.93	-471.76
Issuance of Common Stock	0.37	3.47	13.37	1,579	55.68	2,404
Other Financing Activities	-	-	-	-	-2.58	2.58
Financing Cash Flow	-38.23	-1,736	1.59	3,323	51.18	1,935
Foreign Exchange Rate Adjustments	-	0.11	0	0.35	-0.11	-0.22
Net Cash Flow	-345.45	-677.51	188.87	-175.44	-299.73	1,269
Free Cash Flow	-28.29	6.46	-521.25	-1,353	446.26	-689.22
Free Cash Flow Margin	-4.75%	1.07%	-133.78%	-370.64%	13.60%	-5989.55%
Free Cash Flow Per Share	-0.09	0.02	-1.59	-4.18	1.39	-2.49
Cash Interest Paid	8.54	7.72	7.32	7.53	6.02	16.42
Levered Free Cash Flow	-0.45	-81.08	-164.31	-744.24	-288.35	-601.43
Unlevered Free Cash Flow	5.04	-69.27	-140.83	-727.43	-284.59	-591.17
Change in Working Capital	-9.89	-98.88	534.82	21.39	-1,012	-60.06

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.